Preclinical and mechanistic perspectives on adipose-derived stem cells for atherosclerotic cardiovascular disease treatment
- 16 April 2025
- journal article
- review article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (8) , 4647-4670
Abstract
Adipose-derived mesenchymal stem cells (AD-MSCs) are a promising therapeutic modality for cardiovascular diseases due to their immunomodulatory, anti-inflammatory, and pro-angiogenic properties. This manuscript explores the current status, challenges, and future directions of AD-MSC therapies, focusing on their application in atherosclerosis (AS), myocardial infarction (MI), and heart failure (HF). Preclinical studies highlight AD-MSC’s ability to stabilise atherosclerotic plaques, reduce inflammation, and enhance myocardial repair through mechanisms such as macrophage polarisation, endothelial protection, and angiogenesis. Genetically and pharmacologically modified AD-MSCs, including those overexpressing SIRT1, IGF-1, and PD-L1 or primed with bioactive compounds, exhibit superior efficacy compared to unmodified cells. These modifications enhance cell survival, immunopotency, and reparative capacity, showcasing the potential for tailored therapies. However, clinical translation faces significant hurdles. While recent clinical trials have confirmed the safety of AD-MSC therapy, their efficacy remains inconsistent, necessitating further optimisation of patient selection, dosing strategies, and delivery methods. Donor variability, particularly in patients with co-morbidities like type 2 diabetes (T2D) or obesity, impairs AD-MSC efficacy. Emerging research on extracellular vesicles (EVs) derived from AD-MSC offers a promising cell-free alternative, retaining the therapeutic benefits while mitigating risks. Future perspectives emphasise the need for multidisciplinary approaches to overcome these limitations. Strategies include refining genetic modifications, exploring EV-based therapies, and integrating personalised medicine and advanced diagnostic tools. By addressing these challenges, AD-MSC therapies hold the potential to revolutionise the treatment of cardiovascular diseases, providing innovative solutions to improve patient outcomes. Graphical abstractKeywords
Funding Information
- Russian Science Foundation (25-25-00348)
This publication has 125 references indexed in Scilit:
- Adipose-derived stem cells were impaired in restricting CD4 + T cell proliferation and polarization in type 2 diabetic ApoE −/− mouseMolecular Immunology, 2017
- A Proinflammatory Secretome Mediates the Impaired Immunopotency of Human Mesenchymal Stromal Cells in Elderly Patients with AtherosclerosisStem Cells Translational Medicine, 2017
- Mesenchymal Stem Cell-Derived Extracellular Vesicles as Mediators of Anti-Inflammatory Effects: Endorsement of Macrophage PolarizationStem Cells Translational Medicine, 2017
- Sustained IGF-1 Secretion by Adipose-Derived Stem Cells Improves Infarcted Heart FunctionCell Transplantation, 2016
- MiR-146 and miR-125 in the regulation of innate immunity and inflammationBMB Reports, 2016
- Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indicationsVascular Pharmacology, 2016
- Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppressionStem Cell Research & Therapy, 2015
- The Relative Contribution of Paracine Effect versus Direct Differentiation on Adipose-Derived Stem Cell Transplantation Mediated Cardiac RepairPLOS ONE, 2013
- Simultaneous quantification of six main active constituents in Chinese Angelica by high-performance liquid chromatography with photodiode array detectorPharmacognosy Magazine, 2013
- Secretion of Angiogenic and Antiapoptotic Factors by Human Adipose Stromal CellsCirculation, 2004